Antiviral therapy of hepatitis C in chronic kidney diseases: Meta-analysis of controlled clinical trials

Journal of Viral Hepatitis

Volumn 15, Issue 8, 2008, Pages 600-606

  Fabrizi, F ^a,b   Ganeshan, S V ^b   Lunghi, G ^a   Messa, P ^a   Martin, P ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Chronic kidney disease; Dropout rate; Hepatitis C virus; Meta analysis; Sustained viro logical response

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMANTADINE; LYMPHOBLAST INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; DEPRESSION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GRAFT REJECTION; HEPATITIS C; HUMAN; LEUKOPENIA; META ANALYSIS; MONOTHERAPY; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; CHRONIC DISEASE; DRUG TOXICITY; FEMALE; HEPATITIS C; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 64549118769     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.00990.x     Document Type: Article

References (50)

1. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61.
2. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-1902.
3. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan and the United States: the dialysis outcomes and practice patterns study (DOOPS). J Am Soc Nephrol 2003; 14: 3270-3277.
4. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Hepatitis C virus and death risk in hemodialysis patients. Am J Kidney Dis 2007; 18: 1584-1593.
5. Pereira BJG, Natov SN, Bouthot BA et al. and The New England Organ Bank Hepatitis C Study Group. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998; 53: 1374-1381.
6. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time on renal replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745-750.
7. Mitwalli AH, Alam A, Al-Wakel J et al. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pract 2006; 102: c72-c80.
8. Morales JM, Dominguez-Gil B, Sanz-Gajardo D, Fernandez J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipients on late renal allograft failure. Nephrol Dial Transplant 2004; 19: S72-S76.
9. Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263.
10. Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian HD. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001; 21: 300-306.
11. Maluf DG, Fisher RA, King AL et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation 2007; 83: 853-857.
12. Gourishankar S, Jhangri GS, Tonelli M, Wales LH, Cockfield SM. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant 2004; 4: 1876-1882.
13. Abbott KC, Lentine KL, Bucci JR et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004; 15: 3166-3174.
14. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with post transplant diabetes mellitus in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13: 1374-1380.
15. Kamar N, Mariat C, Delahousse M et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrol Dial Transplant 2007; 22: 1896-1993.
16. Roth D, Cirocco R, Zucker K et al. De novo membranopro-liferative glomerulonephritis in hepatitis C virus infected renal allograft recipients. Transplantation 1995; 59: 1676-1682.
17. Cosio FG, Sedmak DD, Henry ML et al. The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. Transplantation 1996; 62: 1054-1059.
18. Ozdemir BH, Ozdemir FN, Sever S, Colak T, Haberal M. De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc 2006; 38: 492-495.
19. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-1081.
20. Russo MW, Goldsweig C, Jacobson IM, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-1615.
21. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: antiviral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006; 24: 1413-1422.
22. Thevenot T, Regimbau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepatitis 2001; 8: 48-62.
23. Poynard T, Conn HO. The retrieval of randomised clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials 1985; 6: 271-279.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-178.
25. Petitti DB. Approaches to heterogeneity in meta-analysis. Statist Med 2001; 20: 3625-3633.
26. Klein S, Simes J, Blackburn GL. Total parenteral nutrition and cancer clinical trial. Cancer 1986; 58: 1378-1386.
27. Ellis ME, Alfurayh O, Halim MA et al. Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. J Hepatol 1993; 18: 210-216.
28. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant inter-feron alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431.
29. Fernandez JL, Rendo P, del Pino N, Viola L and Nephrolo-gists group for the study of HCV infection. A double-blind controlled trial of recombinant interferon-alfa2b in hae-modialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J Viral Hepatitis 1997; 4: 113-119.
30. Campistol JM, Esforzado N, Martinez J et al. Efficacy and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre-and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704-2709.
31. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained viro-logical and histological response with pretransplant inter-feron therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21: 435-440.
32. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hep 2001; 8: 70-77.
33. Kamar N, Sandres-Saune K, Selves J et al. Long-term riba-virin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-192.
34. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo JM. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal al-lografts by HCV RNA clearance. Am J Transplant 2003; 3: 357-360.
35. Mahmoud IM, Sobh MA, El-Habashi AF et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005; 100: c133-c139.
36. Al-Harbi ASB, Malih GA, Subaity Y, Mansy H, Abutale N. Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transplant 2005; 16: 293-297.
37. Kokoglu OF, Ucmak H, Hosoglu S et al. Efficacy and toler-ability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 575-580.
38. Rendina M, Schena A, Castellaneta NM et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 768-774.
39. Calanca LN, Fehr T, Jochum W et al. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infecion is not superior to ribavirin alone. J Clin Virol 2007; 39: 54-58.
40. Kamar N, Boulestin A, Selves J et al. Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol 2005; 76: 62-68.
41. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988; 7: 889-894.
42. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
43. Gluud L, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C. Cochrane Database Syst Rev 2007 (2); CD002234.
44. Degos F, Pol S, Chaix ML et al. The tolerance and efficacy of interferon alpha in haemodialysis patients with chronic HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-1023.
45. Koenig P, Vogel W, Umlauft F et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507-1509.
46. Hanrotel C, Toupance O, Lavaud S et al. Virological and histological response to 1 year alpha-interferon-2a in he-modialyzed patients with chronic hepatitis C. Nephron 2001; 88: 120-126.
47. Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-2348.
48. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 1991; 44: 127-139.
49. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses.? Lancet 1998; 352: 609-613.
50. Khan KS, Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996; 156: 661-666.